Literature DB >> 23100562

Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.

Henry H Balfour1, Oludare A Odumade, David O Schmeling, Beth D Mullan, Julie A Ed, Jennifer A Knight, Heather E Vezina, William Thomas, Kristin A Hogquist.   

Abstract

BACKGROUND: University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity.
METHODS: EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay.
RESULTS: Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8(+) T-cells but not in numbers of CD4(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003).
CONCLUSIONS: Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23100562      PMCID: PMC3523797          DOI: 10.1093/infdis/jis646

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

Review 1.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Epstein-Barr virus vaccine for the prevention of infectious mononucleosis--and what else?

Authors:  Henry H Balfour
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

Review 3.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load.

Authors:  S L Silins; M A Sherritt; J M Silleri; S M Cross; S L Elliott; M Bharadwaj; T T Le; L E Morrison; R Khanna; D J Moss; A Suhrbier; I S Misko
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

5.  A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease.

Authors:  L A Riddell; A J Pinching; S Hill; T T Ng; E Arbe; G P Lapham; S Ash; R Hillman; S Tchamouroff; D W Denning; J M Parkin
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

6.  Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans.

Authors:  Elena Sandalova; Diletta Laccabue; Carolina Boni; Anthony T Tan; Katja Fink; Eng Eong Ooi; Robert Chua; Bahar Shafaeddin Schreve; Carlo Ferrari; Antonio Bertoletti
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

7.  Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

Authors:  Joseph D Miller; Robbert G van der Most; Rama S Akondy; John T Glidewell; Sophia Albott; David Masopust; Kaja Murali-Krishna; Patryce L Mahar; Srilatha Edupuganti; Susan Lalor; Stephanie Germon; Carlos Del Rio; Mark J Mulligan; Silvija I Staprans; John D Altman; Mark B Feinberg; Rafi Ahmed
Journal:  Immunity       Date:  2008-05-08       Impact factor: 31.745

8.  Simulating Epstein-Barr virus infection with C-ImmSim.

Authors:  Filippo Castiglione; Karen Duca; Abdul Jarrah; Reinhard Laubenbacher; Donna Hochberg; David Thorley-Lawson
Journal:  Bioinformatics       Date:  2007-03-06       Impact factor: 6.937

9.  Primary Epstein-Barr virus infection does not erode preexisting CD8⁺ T cell memory in humans.

Authors:  Oludare A Odumade; Jennifer A Knight; David O Schmeling; David Masopust; Henry H Balfour; Kristin A Hogquist
Journal:  J Exp Med       Date:  2012-03-05       Impact factor: 14.307

10.  The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output.

Authors:  Vey Hadinoto; Michael Shapiro; Chia Chi Sun; David A Thorley-Lawson
Journal:  PLoS Pathog       Date:  2009-07-03       Impact factor: 6.823

View more
  99 in total

Review 1.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Authors:  Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

3.  Primary Epstein-Barr virus infection: impact of age at acquisition, coinfection, and viral load.

Authors:  Henry H Balfour; Priya Verghese
Journal:  J Infect Dis       Date:  2013-03-14       Impact factor: 5.226

Review 4.  Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Authors:  Henry H Balfour
Journal:  Curr Opin Virol       Date:  2014-03-15       Impact factor: 7.090

Review 5.  XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.

Authors:  Feng-Yen Li; Benjamin Chaigne-Delalande; Helen Su; Gulbu Uzel; Helen Matthews; Michael J Lenardo
Journal:  Blood       Date:  2014-02-18       Impact factor: 22.113

6.  Editorial commentary: Genetics and infectious mononucleosis.

Authors:  Henry H Balfour
Journal:  Clin Infect Dis       Date:  2014-04-02       Impact factor: 9.079

7.  The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.

Authors:  Priya S Verghese; David O Schmeling; Jennifer A Knight; Arthur J Matas; Henry H Balfour
Journal:  Transplantation       Date:  2015-03       Impact factor: 4.939

8.  Incidence of Infectious Mononucleosis in Universities and U.S. Military Settings.

Authors:  Yolonda J Williams-Harmon; Leonard A Jason; Ben Z Katz
Journal:  J Diagn Tech Biomed Anal       Date:  2014-11-21

9.  Cognate HLA absence in trans diminishes human NK cell education.

Authors:  Vanessa Landtwing; Ana Raykova; Gaetana Pezzino; Vivien Béziat; Emanuela Marcenaro; Claudine Graf; Alessandro Moretta; Riccarda Capaul; Andrea Zbinden; Guido Ferlazzo; Karl-Johan Malmberg; Obinna Chijioke; Christian Münz
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

10.  Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection.

Authors:  Obinna Chijioke; Anne Müller; Regina Feederle; Mario Henrique M Barros; Carsten Krieg; Vanessa Emmel; Emanuela Marcenaro; Carol S Leung; Olga Antsiferova; Vanessa Landtwing; Walter Bossart; Alessandro Moretta; Rocio Hassan; Onur Boyman; Gerald Niedobitek; Henri-Jacques Delecluse; Riccarda Capaul; Christian Münz
Journal:  Cell Rep       Date:  2013-12-19       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.